Obesity drug market surges as Lilly, Novo Nordisk lead and rivals chase $200B opportunity

Eli Lilly and Novo Nordisk continue to dominate the early market for obesity treatments, expanding their prescription bases with new oral products.

Meanwhile, a range of larger and smaller companies-including Roche, AstraZeneca, Viking Therapeutics and Structure Therapeutics-are positioning themselves to capture a share of the rapidly expanding market.

The sector generated $66 billion in sales last year and analysts project revenues could rise to between $105 billion and $200 billion by 2027, underscoring the sizable growth potential.

A recent William Blair report highlighted recent clinical successes and flagged upcoming data readouts from several firms in the second half of 2026 as key inflection points for the industry.